ArticleTherapeutic advances in neurological disorders2026
Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antithrombotic guidelines for secondary stroke prevention are derived predominantly from Western populations, yet East Asian patients exhibit markedly higher cytochrome P450 2C19 (CYP2C19) loss-of-function allele prevalence (50%-60% vs ~25% in Europeans) - polymorphisms essential for clopidogrel bioactivation - potentially generating population-specific cardiovascular risks not captured in Western-derived recommendations. Objectives: To characterise the 100-day cardiovascular safety and effectiveness of antithrombotic regimens in East Asian ischaemic stroke patients and to develop a pharmacogenomically informed clinical risk prediction model. Design: Nationwide retrospective cohort study. Methods: We analysed 5746 adults from Taiwan's National Health Insurance Research Database (2011-2020) stratified by antithrombotic regimen initiated within 48 h of confirmatory neuroimaging. Primary outcomes - recurrent ischaemic stroke, haemorrhagic stroke, acute myocardial infarction, heart failure and all-cause mortality - were assessed over 100 days. Multivariable Cox regression, propensity score matching, inverse probability weighting, Fine-Gray competing risks models, Results: Dual antiplatelet therapy (DAPT; aspirin plus clopidogrel) was associated with a 17.2-fold increased acute myocardial infarction risk versus aspirin monotherapy (95% confidence interval (CI) 5.61-52.7; number needed to harm 14). This signal was robust across all analytical approaches (propensity-matched hazard ratio (HR) 11.8; inverse probability of treatment weighting HR 13.4; competing-risks subdistribution HR 14.8) and yielded an Conclusion: DAPT is associated with unexpected myocardial infarction risk in East Asian stroke patients, consistent with CYP2C19-mediated pharmacogenomic vulnerability. These findings challenge the universal applicability of Western-derived guidelines and support integration of pharmacogenomic risk stratification into antithrombotic prescribing for East Asian populations. Clinical trial registration: Not applicable (observational study).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.